頭頚部悪性腫瘍に対するCarboquoneとPSKのAdjuvant Therapy

概要

論文の詳細を見る
Effectiveness of adjuvant Chemoimmunotherapy with Carboquone and PS-K was studied in 15 patients. After the initial treatment of cancer, Carboquone in one dose of 0.25mg and PS-K in three doses of 1.0g were given per os every day for at least four weeks up to six months.This therapy was evaluated in the light of clinical progress and immunologic parameters. In the three patients who had previously undergone only palliative treatment, (one had cancer of the maxilla and the other two had cancer of the salivary glands) this therapy was most effective, and the tumors are not apparent now. In most cases, the counts of peripheral lymphocytes were slightly decreased; the skin reactions to Candida extract and PPD were increased; and PHA- and PWM-induced lymphocyte transformations were markedly increased. There were no severe side effects.This study strongly suggests that this adjuvant chemoimmunotherapy is useful at least in cancer of the salivary glands.
耳鼻咽喉科臨床学会の論文